Reuters logo
BRIEF-Ose Immunotherapeutics signs a license option agreement with Inserm
September 28, 2017 / 4:44 PM / 3 months ago

BRIEF-Ose Immunotherapeutics signs a license option agreement with Inserm

Sept 28 (Reuters) - OSE IMMUNOTHERAPEUTICS SA:

* SIGNS A LICENSE OPTION AGREEMENT WITH INSERM TO DEVELOP A NEW CANCER IMMUNOTHERAPY TARGETING MYELOID CELLS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below